Lone H. Ottesen

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 458 citations · Full text

Medicine, Oncology, Pharmacology +17

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist, Ji‐Youn Han, Myung‐Ju Ahn et al. · The Lancet Oncology · 2020 · 413 citations · Full text

Medicine, Oncology, Pharmacology +15

Efficacy of Savolitinib vs Sunitinib in Patients With<i>MET</i>-Driven Papillary Renal Cell Carcinoma

Toni K. Choueiri, Daniel Y.C. Heng, Jae‐Lyun Lee et al. · JAMA Oncology · 2020 · 179 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer

Nasser K. Altorki, Maureen E. Lane, Thomas Bauer et al. · Journal of Clinical Oncology · 2010 · 139 citations · Full text

Medicine, Oncology, Pharmacology +14

Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non–Small Cell Lung Cancer Patients Treated with Pazopanib

Petros Nikolinakos, Nasser K. Altorki, David Yankelevitz et al. · Cancer Research · 2010 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17